Weekly Recap: Trial failures and ~10% share drop, weaker 2030s outlook

Novartis AG (SIX:NOVN) shares plunged after late—stage failures for neuromuscular del—desiran and a cholesterol candidate, prompting analyst downgrades and price—target cuts, even as the company keeps 2025—30 sales guidance, touts a broad pipeline and seeks FDA talks on other candidates.Previous We…